Early safety test of lorcaserin, phentermine conducted
the Clinical Advisor take:
A study of the combination of lorcaserin (Belviq) and phentermine found no major differences in serotonergic adverse effects and possible increased weight loss, according to a report published in MedPage Today.
Lead researcher Steven Smith, MD, of Florida Hospital in Orlando, and colleagues found that patients lost a greater proportion of their body weight over a 12-week period with a combination of the two drugs compared with lorcaserin alone.
The phase II study randomized 238 overweight and obese patients to one of three groups: lorcaserin alone (10 mg twice a day) or lorcaserin plus phentermine (15 mg), either once or twice daily. Each patient received standard weight-loss counseling during the 12-week trial.
The researchers looked primarily at the proportion of patients reporting at least one of nine common potential serotonergic adverse events: headache, dizziness, nausea, fatigue, dry mouth, diarrhea, vomiting, insomnia, or anxiety.
The researchers found that this primary endpoint occurred in a similar proportion across all three groups, with the most common adverse effects being dry mouth, headache, constipation, fatigue, and dizziness. However, more patients in the twice-daily phentermine group discontinued due to adverse effects. The addition of phentermine also diminished improvements in blood pressure and heart rate seen with only lorcaserin.
Adam Tsai, MD, of Kaiser Permanente Colorado in Denver and chair of The Obesity Society's public affairs committee, said the question will be whether the weight-loss benefits of the combination will outweigh the increases in these cardiovascular risk markers.
Lorcaserin and phentermine have passed an early safety test.
BOSTON -- An early study of the combination of lorcaserin (Belviq) and phentermine showed no major differences in its primary endpoint of serotonergic adverse effects, and hinted at greater weight loss, researchers reported here.
In a phase II study, patients lost a greater proportion of their body weight over 12 weeks when adding twice-daily phentermine to their lorcaserin prescription, compared with lorcaserin alone (8.7% versus 3.8%), according to Steven Smith, MD, of Florida Hospital in Orlando, and colleagues.
But reductions in blood pressure and pulse rate were not as great for those who added phentermine to their regimens -- and the highest-dose phentermine group had an increase in heart rate -- but a clinician who works for Eisai emphasized that the study was not powered to look at the weight loss or cardiovascular endpoints.
Next Article in Web Exclusives
Sign Up for Free e-newsletters
Clinical Advisor Articles
- Opioids for chronic pain: a new clinical guideline from the VA and Department of Defense
- 2017 Adult immunization schedule released by the CDC
- Apixaban linked to higher rates of stroke than warfarin in patients with atrial fibrillation
- Hepatitis C infection linked to nonhepatic cancers among elderly patients
- MRI may detect autism before age 1
- Sepsis and septic shock: new guidelines for clinical management
- Vulvar lichen sclerosus: breaking the silence
- Noninvasive treatment for low back pain: a new clinical guideline from ACP
- Cannabis health risks and benefits: a report from NASEM
- Earwax: a clinical practice guideline for management and treatment
- Fruit and vegetable consumption reduces risk of COPD in smokers
- Exercise may improve cognitive function ater stroke
- Vitamin D supplementation reduces the risk of acute respiratory tract infection
- Proton pump inhibitor use may decrease healthcare visits in GERD patients
- More antimicrobial treatments needed in community-acquired pneumonia